Haihe Biopharma Co., Ltd.
19
4
5
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.8%
3 terminated/withdrawn out of 19 trials
66.7%
-19.8% vs industry average
0%
0 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Role: lead
Evaluate the Safety and Clinical Activity of HH2853
Role: lead
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Role: lead
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)
Role: lead
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
Role: lead
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Role: lead
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Role: lead
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
Role: lead
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Role: lead
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
Role: lead
Single Dose Glumetinib in Healthy Chinese Male Subjects
Role: lead
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
Role: lead
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
Role: lead
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
Role: lead
This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients
Role: lead
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
Role: lead
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
Role: lead
Study of the AL3810 in the Treatment of Advanced Solid Tumor
Role: lead
Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor
Role: lead
All 19 trials loaded